Cevimeline Hydrochloride Hydrate

西维美林

Report date: 2022/08/17 14:43:16
NME

Base Information

Drug NameCevimeline Hydrochloride Hydrate
Drug Alias Name盐酸西维美林水合物cevimelinumcevimelinacevimelineSaligren +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 agonistsMuscarinic acetylcholine receptor M1 agonists
TargetsMuscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3
Therapy Area/IndicationsRadiation InjuriesXerostomiaMouth Diseases +[5] 
Global Approved IndicationsSjogren's Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2000/01/11
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCosette Pharmaceuticals IncDaiichi Sankyo Co LtdNippon Kayaku Co Ltd
Inactive CompaniesRoxane Laboratories IncZhuhai Yibang Pharmaceutical Co Ltd
Active IndicationsSjogren's Syndrome
Inactive IndicationsRadiation InjuriesXerostomiaMouth Diseases +[4] 

Other Information

ATC CodeN07AX03
Related LinksWikipediaDrugBankKEGG